Private Equity Archives - Gilde Healthcare

Menu
Menu
Home

News

News

News
Venture&Growth

News
Private Equity

Gilde Healthcare’s Private Equity-Fonds kombiniert Artinis und NIRx zu einer weltweit führenden Neuroimaging-Gruppe

Gilde Healthcare gibt heute eine kombinierte Private-Equity-Investition in Artinis Medical Systems (Niederlande) und NIRx Medical Technologies (Deutschland/Vereinigte Staaten) bekannt. Beide Unternehmen sind Pioniere auf dem Gebiet der funktionellen Nahinfrarot-Spektroskopie (fNIRS)....

8 July 2025

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...

9 July 2025

Gilde Healthcare’s Private Equity-Fonds kombiniert Artinis und NIRx zu einer weltweit führenden Neuroimaging-Gruppe

Gilde Healthcare gibt heute eine kombinierte Private-Equity-Investition in Artinis Medical Systems (Niederlande) und NIRx Medical Technologies (Deutschland/Vereinigte Staaten) bekannt. Beide Unternehmen sind Pioniere auf dem Gebiet der funktionellen Nahinfrarot-Spektroskopie (fNIRS)....

8 July 2025

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...

9 July 2025

Filter & Suche

Fondsstrategie :
  • Alle
  • Private Equity
  • Venture&Growth
Suche:

Gilde Healthcare’s Private Equity-Fonds kombiniert Artinis und NIRx zu einer weltweit f...

Gilde Healthcare gibt heute eine kombinierte Private-Equity-Investition in Artinis Medical Systems (Niederlande) und NIRx Medical Technologies (Deutschland/Vereinigte Staaten) bekannt. Beide Unternehmen sind Pioniere auf dem Gebiet der funktionellen Nahinfrarot-Spektroskopie (fNIRS). Die Transaktion vereint zwei hochkomplementäre Unternehmen und kreiert dabei einen neuen globalen Marktführer im Bereich fNIRS. Weiterentwicklung...
8. Juli 2025

Gilde Healthcare announces successful sale of health-it software company Performation to E...

Exit confirms Gilde Healthcare’s investment strategy of building market-leading healthcare companies that deliver better care at lower cost Under ownership of Gilde Healthcare’s private equity fund, Performation has evolved into a leading European SaaS healthcare platform through seven strategic acquisitions and product innovations Revenue more than doubled...
13. Februar 2025

Gilde Healthcare company NIZO participates in national consortium investing in precision f...

The Netherlands is strengthening its position as a global leader in cellular agriculture with the launch of two independent, open-access scale-up facilities. These facilities, developed in a collaboration between NIZO Food Research, Cultivate at Scale (CaS), Cellular Agriculture Netherlands Foundation (CAN), Biotechnology Fermentation Factory Ede (BFF), Mosa...
4. Februar 2025

Gilde Healthcare invests alongside Capital A in Tromp Medical to accelerate international ...

Tromp Medical, Europe’s largest independent medical imaging sales and service organization, has attracted Gilde Healthcare as new investor to drive further growth in the medical imaging market. Headquartered in the Netherlands, Tromp Medical specializes in installing and maintaining various medical imaging equipment modalities such as mammography, CT,...
16. Dezember 2024

GILDE HEALTHCARE COMPANY SYNEXA LIFE SCIENCES ACQUIRES ALDERLEY ANALYTICAL TO EXPAND BIOAN...

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning the company’s vision to be ‘the scientific partner of choice for biomarker...
3. Oktober 2024

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the lea...

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in the healthcare market. Strengthening their joint position will further elevate service levels...
5. Juli 2024

Gilde Healthcare veräussert RAD-x an ein konsortium aus Swiss Life Asset Managers und Ves...

Gilde Healthcare´s Private Equity Fund (“Gilde Healthcare”), ein auf das Gesundheitswesen spezialisierter Investor, hat eine bindende Vereinbarung über den Verkauf seiner Mehrheitsbeteiligung an RAD-x an ein Konsortium aus Swiss Life Asset Managers und Vesper Next Generation Infrastructure Fund I unterzeichnet. Gilde Healthcare investierte in RAD-x und gründete...
18. März 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership wi...

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V., a Givaudan group company. With this move, NIZO widens its capabilities and...
29. Februar 2024

Gilde Healthcare portfolio company Scharenborg Group appoints Johannes Schneider Littfeld ...

The Scharenborg Group, a leading footcare technology firm has appointed Johannes Schneider Littfeld as Chairman to the Advisory Board. Johannes is an experienced executive in the MedTech- and patient care industry. He spent 15 years in senior management of Otto Bock, the global leader in Orthopedic Technology....
8. Februar 2024
Loading...
Das waren alles Artikel
9e1dcc2192